In this episode of TransplantRPh, April discusses the latest updates in neurology, including advancements in treatments for cerebrovascular disease, epilepsy, headache, movement disorders, neuromuscular disease, and neurooncology. Connect with April on LinkedIn at April Oliveros, YouTube at Pharmacist April, Instagram at PharmacistApril, or via email at [email protected]. Don’t miss her new e-book providing a step-by-step guide for foreign pharmacy graduates on becoming pharmacists in the USA! https://stan.store/pharmacistapril

Detailed Notes:

Surgical Decompression for Severe Cerebral Venous Thrombosis:Hemicraniectomy shows promise in selected cases, particularly younger patients with less severe preoperative findings.

- Mechanical Thrombectomy for Extremely Large Core Infarcts: May benefit patients with ASPECTS of 0 to 2, challenging existing selection criteria.

- Reversal Strategy for Intracerebral Hemorrhage: Andexanet alfa demonstrates higher hemostasis rates but increased thrombotic events.

- Risk of Epilepsy After Aneurysmal Subarachnoid Hemorrhage: 12% of patients develop epilepsy within seven months, with several identified risk factors.

- CGRP Antagonists for Migraine Prevention: Now considered first-line therapy based on efficacy and safety.

- GLP-1 Receptor Agonists in Parkinson Disease: Mixed results in trials; larger studies needed.

- Suicidality in Parkinson Disease: 22% prevalence of suicidal ideation; importance of depression screening and treatment.

- Efgartigimod Alfa-Hyaluronidase in CIDP: Shows significant improvement and reduced clinical deterioration.

- Behavioral Therapy in ALS: ACT improves quality of life in ALS patients.

- Tovorafenib in Pediatric Low-Grade Gliomas: Shows promising response rates and duration in BRAF-altered gliomas.

- ONC201 in H3 K27M-Mutant Diffuse Midline Glioma: Promising activity with a 20% response rate and median duration of 11.2 months.